Search

Current Active Cancer Clinical Trials 

Active Clinical Trials - Cancer Trial CoordinatorsFor additional information about Cancer Clinical Trials at the Virginia G. Piper Cancer Center please contact the Clinical Trial Patient Care Coordinator at 480-323-1339 (toll free: 1-877-273-3713), or e-mail clinicaltrials@shc.org.

You may search for clinical trials by Tumor Type and/or Keyword.

 

Protocol # Sponsor Title  
391101 Baxter Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
3V2640-CLIN-002 3-V Biosciences A Phase 1, First-in-human Study of Escalating Doses of Oral TVB-2640 in Patients with Solid Tumors
673-301 BioMarin A Study Evaluating BMN 673, a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation
ADU-CL-04 Aduro Efficacy of Combination Listeria/GVAX Immunotherapy in the Pancreatic Cancer Setting (ECLIPSE)
AG120-C-002 Agios Study of Orally Adminstered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
AZA-ST001 Celgene A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
EC1169-01 Endocyte A Phase 1 Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin conjugate EC1169 in Patients with recurrent metastatic, castration-resistant prostate cancer (mCRPC).
EC1456-01 Endocyte Folic Acid-Tubulysin conjugate EC1456 in patients with advanced solid tumors
EMR 100070-001 EMD Serono A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.
IDC-G305-12013-001 Immune Design A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
INCB 18424-267 Incyte A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
INCB 39110-116 Incyte Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
M12-375 Abbott Study of ABT-700 in Subjects With Advanced Solid Tumors
M14-011 Abbvie A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
MINNELIDE 001 Minneamrita Study of Minnelide™ in Patients With Advanced GI Tumors
MK3475-028-00 Merck Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
MRX34-101 MiRNA A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension
NA 00090282 SU2C An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy after Induction Chemotherapy in Subjects with Metastatic Pancreatic Adenocarcinoma
NP28902 Roche A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION
PCRT 12-001 Seena Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
PLX108-01 Plexxikon Safety Study of PLX108-01 in Patients With Solid Tumors - At This Time, All Cohorts Are Closed to Enrollment With the Exception of the Pigmented Villo-nodular Synovitis (PVNS) Cohort.
PLX119-01 Plexxikon Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors
PLX120-01 Plexxikon a Phase I/Iia Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 with Advanced Unresectable Solid Tumors
PMT4979g Genentech A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
PR-20-5006-C Tesaro A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
PRP-001 BioMarin Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
SM04755-ONC-01 Samumed A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
SNX-5422-CLIN1-008 Esanex Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
SU2C-005 SU2C-005 A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
SU2C-007 SU2C 007 A Pharmacodynamic study of the Nab-Paclitaxel/Gemcitabine combo given weekly 3x as induction therapy followed by maintenance every 2 weeks in patients with metastatic pancreatic cancer
TKM-PLK1-001 Tekmira A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
VS-5584-101 Verastem Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma